Fintel reports that on May 21, 2026, Stifel initiated coverage of Eupraxia Pharmaceuticals (NasdaqCM:EPRX) with a Buy recommendation.
Analyst Price Forecast Suggests 89.83% Upside
As of May 14, 2026, the average one-year price target for Eupraxia Pharmaceuticals is $12.09/share. The forecasts range from a low of $10.24 to a high of $16.05. The average price target represents an increase of 89.83% from its latest reported closing price of $6.37 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Eupraxia Pharmaceuticals is 46MM. The projected annual non-GAAP EPS is -0.54.
What is the Fund Sentiment?
There are 57 funds or institutions reporting positions in Eupraxia Pharmaceuticals. This is an increase of 19 owner(s) or 50.00% in the last quarter. Average portfolio weight of all funds dedicated to EPRX is 0.26%, an increase of 49.99%. Total shares owned by institutions increased in the last three months by 63.47% to 21,985K shares.
What are Other Shareholders Doing?
Beutel, Goodman & Co holds 3,666K shares representing 5.96% ownership of the company. In its prior filing, the firm reported owning 3,709K shares , representing a decrease of 1.17%. The firm increased its portfolio allocation in EPRX by 4.23% over the last quarter.
Affinity Asset Advisors holds 1,589K shares representing 2.58% ownership of the company. In its prior filing, the firm reported owning 300K shares , representing an increase of 81.12%. The firm increased its portfolio allocation in EPRX by 360.36% over the last quarter.
Balyasny Asset Management holds 1,350K shares representing 2.20% ownership of the company. No change in the last quarter.
Vivo Capital holds 1,350K shares representing 2.20% ownership of the company. No change in the last quarter.
Scotia Capital holds 1,342K shares representing 2.18% ownership of the company. In its prior filing, the firm reported owning 1,286K shares , representing an increase of 4.17%. The firm decreased its portfolio allocation in EPRX by 23.02% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
